

Supporting Information for

Metal-free Tandem Cyclization/Hydrosilylation to Construct Tetrahydroquinoxalines

Yixiao Pan,^a Changjun Chen,^a Xin Xu,^a Haoqiang Zhao,^a Jiahong Han,^a Huanrong Li,^a
Lijin Xu,^{a*} Qinghua Fan^{b*} and Jianliang Xiao^{c*}

^a Department of chemistry, Renmin University of China, Beijing 100872, China.

^b Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.

^c Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, U.K.

Email: 20050062@ruc.edu.cn; fanqh@iccas.ac.cn; J.Xiao@liverpool.ac.uk

Contents:


1. General information-----	S2
2. Determination of the optimal reaction conditions-----	S2
3. General procedure for the synthesis of tetrahydroquinoxalines-----	S8
4. Characterization of the products-----	S10
5. The mechanistic study-----	S23
6. References-----	S25
7. ¹ H and ¹³ C NMR spectra of the products-----	S27
8. HPLC Charts-----	S88

1. General information:

Unless otherwise noted, all experiments were carried out in air, and all commercially available chemicals including organic solvents were used as received from Aldrich, Acros or Strem without further purification. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Model Avance DMX 400 Spectrometer (^1H 400 MHz and ^{13}C 100.6 MHz, respectively). Chemical shifts (δ) are given in ppm and are referenced to residual solvent peaks. 4,5-Dibromobenzene-1,2-diamine (**1m**),¹ 4,5-dimethoxybenzene-1,2-diamine (**1n**),² α -ketoesters^{3,4a}, chiral diene ligands^{4b} and $\text{HB}(\text{C}_6\text{F}_5)_2$ ^{4b} were prepared according to the previous reports.

2. Determination of the optimal reaction conditions

Table S1. Screening of hydrosilanes.^a

				
Entry	hydrosilane	3aa (%) ^b	4aa (%) ^b	5aa (%) ^b
1	PhSiH ₃	67	25	3
2	Ph ₂ SiH ₂	73	20	4
3	Et ₃ SiH	68	20	8
4	(EtO) ₃ SiH	62	27	10
5	EtMe ₂ SiH	71	23	2
6	Me ₂ PhSiH	25	60	13
7	TMDS	42	50	2
8	PMHS	80	13	2

^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), $\text{B}(\text{C}_6\text{F}_5)_3$ (5.0 mol%), THF (1.5 mL), hydrosilane (1.0 mmol) at 110 °C for 16 h. ^b Yield determined by ^1H NMR with CH_2Br_2 as an internal standard.


Table S2. Screening of catalysts.^a

$\text{1a} + \text{2a} \xrightarrow[\text{PMHS, THF, 110 } ^\circ\text{C, 16 h}]{\text{Catalyst (5.0 mol\%)}} \text{3aa} + \text{4aa} + \text{5aa}$

Entry	Catalyst	3aa (%) ^b	4aa (%) ^b	5aa (%) ^b
1	B(C₆F₅)₃	80	13	2
2	BF ₃ -OEt ₂	12	18	68
3	BEt ₃	3	20	73
4	BPh ₃	<1	<1	95
5	InCl ₃	60	25	12
6	Fe ₃ (CO) ₁₂	45	35	16
7	Zn(OAc) ₂	10	15	73
8	Cu(OTf) ₂	12	15	62
9	Co(acac) ₃	3	11	82
10	Co(acac) ₂	2	25	67
11	Co ₂ (CO) ₈	23	36	37
12	Ni(acac) ₂	3	22	71
13		4	12	82
14		3	15	77
15		4	18	75
16		7	41	50


^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), catalyst (5.0 mol%), THF (1.5 mL), PMHS (1.0 mmol) at 110 °C for 16 h. ^b Yield determined by ¹H NMR with CH₂Br₂ as an internal standard.

Table S3. Screening of solvents.^a

				
Entry	Solvent	3aa (%) ^b	4aa (%) ^b	5aa (%) ^c
1	THF	80	13	2
2	1,4-dioxane	78	12	8
3	dibutyl ether	88	10	<1
4	1,2-dimethoxyl ethane	40	51	4
5	CH ₂ Cl ₂	47	32	18
6	1,2-dichloroethane	53	26	16
7	toluene	94	3	<1
8	<i>p</i> -xylene	90	5	3
9	PhCl	88	10	<1
10	PhF	86	7	3
11	<i>tert</i> -butyl methyl ether	83	10	3
12	MeCN	62	25	10
13	ethanol	36	12	45
14	isopropanol	43	32	20
15	DMSO	4	12	80
16	DMF	4	3	85

^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), B(C₆F₅)₃ (5.0 mol%), solvent (1.5 mL), PMHS (0.06 mL, 1.0 mmol) at 110 °C for 16 h. ^b Yield determined by ¹H NMR with CH₂Br₂ as an internal standard.


Table S4. Screening of catalyst loadings.^a



Entry	X (mol%)	3aa (%) ^b	4aa (%) ^b	5aa (%) ^b
1	10	93	2	<1
2	8	92	3	<1
3	6	94	3	<1
4	5	94	3	<1
5	4	88	9	<1
6	2	73	23	3
7	1	44	50	4

^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), B(C₆F₅)₃, toluene (1.5 mL), PMHS (0.06 mL, 1.0 mmol) at 110 °C for 16 h. ^b Yield determined by ¹H NMR with CH₂Br₂ as an internal standard.







Table S5. Screening of reaction temperature.^a



Entry	Temperature (°C)	3aa (%) ^b	4aa (%) ^b	5aa (%) ^b
1	140	92	4	<1
2	130	93	3	<1
3	120	94	3	<1
4	110	94	3	<1
5	100	91	6	<1
6	80	86	12	<1
7	60	75	15	8


^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), B(C₆F₅)₃ (5.0 mol%), PMHS (0.06 mL, 1.0 mmol), toluene (1.5 mL) at 110 °C for 16 h. ^b Yield determined by ¹H NMR with CH₂Br₂ as an internal standard.

Table S6. Variation of the amount of PMHS.^a

 1a  2a   3aa  4aa  5aa				
Entry	X (equiv.)	3aa (%) ^b	4aa (%) ^b	5aa (%) ^b
1	5	92	3	<1
2	4	94	4	<1
3	3	83	13	<1
4	2	35	64	<1
5	1.5	20	75	<1
6	1	7	65	25

^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), B(C₆F₅)₃ (5.0 mol%), toluene (1.5 mL), PMHS (0.06 mL, 1.0 mmol) at 110 °C for 16 h. ^b Yield determined by ¹H NMR with CH₂Br₂ as an internal standard.


Table S7. Preliminary optimization studies for asymmetric synthesis of **3aa**.^a



Entry	hydrosilane	solvent	Temp (°C)	3aa (%) ^b	ee (%) ^c
1	PMHS	toluene	110	92	racemic
2	PMHS	THF	110	86	18
3	PMHS	<i>n</i> Bu ₂ O	110	88	11
4	PMHS	1,4-dioxane	110	78	6
5	PMHS	1,2-dimethoxyl ethane	110	72	racemic
6	PMHS	<i>tert</i> -butyl methyl ether	110	76	11
7	PMHS	CH ₂ Cl ₂	110	43	racemic
8	PMHS	1,2-dichloroethane	110	66	5
9	PMHS	MeCN	110	58	racemic
10	PMHS	<i>i</i> PrOH	110	21	racemic
11	PMHS	<i>p</i> -xylene	110	88	racemic
12	PMHS	PhCl	110	81	12
13	PMHS	PhF	110	84	13
14	PMHS	THF	90	85	18
15	PMHS	THF	70	84	28
16	PMHS	THF	50	71	28
17	Ph₂SiH₂	THF	70	87	47
18	Et ₃ SiH	THF	70	76	32
19	(EtO) ₃ SiH	THF	70	72	27
20	EtMe ₂ SiH	THF	70	68	racemic
21	Me ₂ PhSiH	THF	70	72	12
22	TMDS	THF	70	52	14
23	Ph ₂ SiH ₂	THF	50	62	47
24 ^d	Ph ₂ SiH ₂	THF	70	87	44

25 ^e	Ph ₂ SiH ₂	THF	70	85	41
26 ^f	Ph ₂ SiH ₂	THF	70	86	42

^a Reaction conditions: **1a** (0.25 mmol), **2a** (0.275 mmol), HB(C₆F₅)₂ (10.0 mol%), **6** (5.0 mol%), solvent (1.5 mL), hydrosilane (1.0 mmol) for 16 h. ^b Isolated yield. ^c The ee values were determined by HPLC using a Chiralcel OD-H column. ^d Chiral diene **7** was employed. ^e Chiral diene **8** was employed. ^f Chiral diene **9** was employed.



3. General procedure for the synthesis of tetrahydroquinoxalines

(1) General procedure for the synthesis of 2-substituted tetrahydroquinoxalines

To an oven-dried screw-capped pressure tube were sequentially added 1,2-diaminobenzene **1** (0.25 mmol), α -ketoester **2** (0.275 mmol), B(C₆F₅)₃ (6.4 mg, 5.0 mol%), PMHS (0.06 mL, 1.0 mmol) and toluene (1.5 mL). Then the reaction mixture was stirred at 110 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0 mL) was added to the reaction mixture, which was extracted with EtOAc three times (5.0 mL each). The combined organic phases were dried over Na₂SO₄, then filtered and evaporated under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by silica gel column chromatography using a mixture of EtOAc and hexane to give the corresponding pure product.

(2) General procedure for the synthesis of 3,4-dihydroquinoxalin-2(1H)-ones

To an oven-dried screw-capped pressure tube were sequentially added 1,2-diaminobenzene **1** (0.25 mmol), α -ketoester **2** (0.275 mmol), B(C₆F₅)₃ (6.4 mg, 5.0 mol%), PMHS (22.5 μ L, 0.375 mmol) and toluene (1.5 mL). Then the reaction mixture was stirred at 110 °C for 3 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0 mL) was added to the reaction mixture, which was then extracted with EtOAc three times (5.0 mL each). The combined organic phases were dried over Na₂SO₄, then filtered and evaporated under reduced pressure.

After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by silica gel column chromatography using a mixture of EtOAc and hexane to give the corresponding pure product.

(3) General procedure for grammar-scale transformation reaction

To an oven-dried screw-capped pressure tube were sequentially added 1,2-diaminobenzene **1a** (1.08 g, 10.0 mmol), ethyl 2-oxopropanoate **2a** (1.28 g, 11.0 mmol), B(C₆F₅)₃ (250.0 mg, 5.0 mol%), PMHS (2.4 mL, 40.0 mmol) and toluene (60.0 mL). Then the reaction mixture was stirred at 110 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (120.0 mL). Then water (100.0 mL) was added to the reaction mixture, which was extracted with EtOAc five times (30.0 mL each). The combined organic phases were dried over Na₂SO₄, then filtered and evaporated under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by silica gel column chromatography using a mixture of EtOAc and hexane to give pure **3aa** (yellow solid, 1.3 g, 90%).

(4) General procedure for asymmetric synthesis of 2-substituted tetrahydroquinoxalines

To an oven-dried screw-capped pressure tube were sequentially added 1,2-diaminobenzene **1** (0.25 mmol), α -ketoester **2** (0.275 mmol), HB(C₆F₅)₂ (8.67 mg, 10.0 mol%), chiral diene **6** (7.88 mg, 5.0 mol%), Ph₂H₂Si (0.185 mL, 1.0 mmol) and THF (1.5 mL). Then the reaction mixture was stirred at 70 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0 mL) was added to the reaction mixture, which was extracted with EtOAc three times (5.0 mL each). The combined organic phases were dried over Na₂SO₄, then filtered and evaporated under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by silica gel column chromatography using a mixture of EtOAc and hexane to give the pure product.


(5) General procedure for asymmetric synthesis of 3,4-dihydroquinoxalin-2(1H)-ones

To an oven-dried screw-capped pressure tube were sequentially added 1,2-diaminobenzene **1** (0.25 mmol), α -ketoester **2** (0.275 mmol), HB(C₆F₅)₂ (8.67 mg, 10.0 mol%), chiral diene **6** (7.88 mg, 5.0 mol%), Ph₂H₂Si (0.069 mL, 0.375 mmol) and THF (1.5 mL). Then the reaction mixture was stirred at 45 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0

mL) was added to the reaction mixture, which was extracted with EtOAc five times (5.0 mL each). The combined organic phases were dried over Na₂SO₄, then filtered and evaporated under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by silica gel column chromatography using a mixture of EtOAc and hexane to give the pure product.


4. Characterization of the products

2-Methyl-1,2,3,4-tetrahydroquinoxaline (3aa)⁵




Yellow solid, mp: 71-72 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.99-6.13 (m, 4H), 4.05 (s, 2H), 3.60-3.40 (m, 2H), 3.12-2.89 (m, 1H), 1.15 (dd, *J* = 17.4, 6.5 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 134.37, 133.58, 133.15, 118.81, 118.76, 114.57, 48.23, 45.73, 19.90; HRMS (ESI) calcd. for C₉H₁₃N₂ [M+H]⁺: 149.1073, found: 149.1075.

2-Ethyl-1,2,3,4-tetrahydroquinoxaline (3ab)⁵




Yellow solid, mp: 67-69 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.59-6.48 (m, 4H), 3.41-3.36 (m, 1H), 3.32 (ddd, *J* = 14.1, 6.7, 2.9 Hz, 1H), 3.08-3.04 (m, 1H), 1.55-1.48 (m, 2H), 1.00 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.41, 133.15, 118.97, 118.72, 114.60, 51.71, 46.21, 27.06, 10.03; HRMS (ESI) calcd. for C₁₀H₁₅N₂ [M+H]⁺: 163.1230, found: 163.1227.

2-Propyl-1,2,3,4-tetrahydroquinoxaline (3ac)⁶




Brown-yellow solid, mp: 66-67 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.60-6.58 (m, 2H), 6.50 (dd, *J* = 8.4, 4.1 Hz, 2H), 3.36-3.34 (m, 2H), 3.08-3.03 (m, 1H), 1.47-1.44 (m, 4H), 0.97 (td, *J* = 6.8, 3.9 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.53, 133.41, 118.76, 118.61, 114.49, 114.44, 53.45, 49.99, 36.44, 18.86, 14.16; HRMS (ESI) calcd. for C₁₁H₁₇N₂ [M+H]⁺: 177.1386, found: 177.1388.

2-Isopropyl-1,2,3,4-tetrahydroquinoxaline (3ad)⁷




Brown solid, mp: 73-75 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.59-6.48 (m, 4H), 3.37-3.34 (m, 1H), 3.11 (dt, *J* = 14.0, 6.7 Hz, 1H), 1.76-1.67 (m, 1H), 0.98 (ddd, *J* = 21.7, 14.8, 6.9 Hz, 6H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.87, 133.36, 118.84, 118.39, 114.37, 114.32, 56.00, 53.44, 31.03, 18.73; HRMS (ESI) calcd. for C₁₁H₁₇N₂ [M+H]⁺: 177.1386, found: 177.1395.

2-Butyl-1,2,3,4-tetrahydroquinoxaline (3ae)⁷




Brown solid; mp: 58-59°C; ¹H NMR (400 MHz, CDCl₃) δ 6.59-6.53 (m, 2H), 6.52-6.51 (m, 2H), 3.38 (d, *J* = 8.5 Hz, 2H), 3.07 (dd, *J* = 17.8, 6.9 Hz, 1H), 1.51-1.36 (m, 6H), 0.95 (dd, *J* = 9.1, 5.0 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 134.37, 133.58, 133.15, 118.79, 118.62, 114.47, 50.24, 46.66, 33.98, 31.68, 27.82, 21.05, 14.20; HRMS (ESI) calcd. for C₁₂H₁₉N₂ [M+H]⁺: 191.1543, found: 191.1548.

2-Isobutyl-1,2,3,4-tetrahydroquinoxaline (3af)⁸




Yellow solid, mp: 69-70°C; ¹H NMR (400 MHz, CDCl₃) δ 6.65-6.40 (m, 4H), 3.62 (s, 2H), 3.43 (qd, *J* = 7.8, 2.8 Hz, 1H), 3.33 (dd, *J* = 10.7, 2.8 Hz, 1H), 3.14-2.85 (m, 1H), 1.74 (dp, *J* = 13.3, 6.7 Hz, 1H), 1.44-1.24 (m, 3H), 0.99-0.90 (m, 6H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.57, 133.52, 118.77, 118.69, 114.60, 114.49, 48.18, 47.09, 43.41, 24.53, 23.24, 22.59; HRMS (ESI) calcd. for C₁₂H₁₉N₂ [M+H]⁺: 191.1543, found: 191.1550.

2-(Tert-butyl)-1,2,3,4-tetrahydroquinoxaline (3ag)⁸




Yellow solid, mp: 82-83°C; ¹H NMR (400 MHz, CDCl₃) δ 6.656.44 (m, 4H), 3.80-3.47 (m, 1H), 3.45-3.23 (m, 1H), 3.23-2.88 (m, 2H), 0.98 (s, 9H); ¹³C NMR (100.6 MHz, CDCl₃) δ 134.57, 133.36, 118.85, 118.24, 114.32, 114.25, 59.02, 42.52, 32.79, 26.05; HRMS (ESI) calcd. for C₁₂H₁₉N₂ [M+H]⁺: 191.1543, found: 191.1546.

2-Hexyl-1,2,3,4-tetrahydroquinoxaline (3ah)⁸




Yellow solid, mp: 74-76°C; ¹H NMR (400 MHz, CDCl₃) δ 6.54 (dq, *J* = 29.5, 4.6 Hz, 4H), 3.62 (s, 1H), 3.40-3.25 (m, 1H), 3.04 (dd, *J* = 11.1, 8.4 Hz, 1H), 1.59-1.16 (m, 10H), 0.89 (t, *J* = 6.5 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.58, 133.47, 118.72, 118.59, 114.47, 114.42, 50.27, 46.72, 34.34, 31.81, 29.41, 25.64, 22.65, 14.13; HRMS (ESI) calcd. for C₁₄H₂₃N₂ [M+H]⁺: 219.1856, found: 219.1866.

2-Cyclohexyl-1,2,3,4-tetrahydroquinoxaline (3ai)⁸




Yellow solid, mp: 105-106°C; ¹H NMR (400 MHz, CDCl₃) δ 6.63-6.53 (m, 2H), 6.52-6.42 (m, 2H), 3.67 (s, 2H), 3.36 (dd, *J* = 10.4, 2.3 Hz, 1H), 3.24-3.03 (m, 2H), 1.92-1.63 (m, 5H), 1.54-1.36 (m, 1H), 1.33-0.95 (m, 6H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.77, 133.42, 118.69, 118.28, 114.26, 55.12, 43.90, 40.65, 29.11, 28.88, 26.39, 26.12, 26.07; HRMS (ESI) calcd. for C₁₄H₂₁N₂ [M+H]⁺: 217.1699, found: 217.1705.

2-Benzyl-1,2,3,4-tetrahydroquinoxaline (3aj)⁶




Yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.17 (m, 5H), 6.62-6.35 (m, 4H), 3.65-3.53 (m, 1H), 3.37 (dd, *J* = 10.8, 2.8 Hz, 1H), 3.15 (dd, *J* = 10.7, 7.1 Hz, 1H), 2.89-2.75 (m, 1H), 2.75-2.59 (m, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 138.05, 133.29, 133.07, 129.33, 128.72, 126.67, 118.87, 118.79, 114.64, 114.49, 51.29, 46.29, 40.58, 29.76; HRMS (ESI) calcd. for C₁₅H₁₇N₂ [M+H]⁺: 225.1386, found: 225.1379.

2-(Trifluoromethyl)-1,2,3,4-tetrahydroquinoxaline (3ak)




Pale-yellow oil; ¹H NMR (400 MHz, DMSO) δ 7.92 (d, *J* = 8.0 Hz, 1H), 7.73 (t, *J* = 7.3 Hz, 1H), 7.42 (t, *J* = 7.9 Hz, 2H), 4.38 (t, *J* = 4.8 Hz, 1H), 3.44 (tt, *J* = 17.0, 8.5 Hz, 2H); ¹³C NMR (100.6 MHz, DMSO) δ 152.17, 134.20, 133.96, 130.34, 124.63, 116.33, 56.48, 55.38, 19.02; HRMS (ESI) calcd. for C₉H₁₀F₃N₂ [M+H]⁺: 203.0791, found: 203.0793.


2-Phenyl-1,2,3,4-tetrahydroquinoxaline (3al)⁹




Yellow solid, mp: 121-123 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.28 (m, 5H), 6.70-6.53 (m, 4H), 4.48 (dd, *J* = 8.2, 3.1 Hz, 1H), 3.46 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.32 (dd, *J* = 11.0, 8.2 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 134.13, 132.82, 128.65, 127.91, 127.01, 118.90, 118.78, 114.70, 114.43, 53.46, 49.15; HRMS (ESI) calcd. for C₁₄H₁₅N₂ [M+H]⁺: 211.1230, found 211.1233.

2-(*p*-Tolyl)-1,2,3,4-tetrahydroquinoxaline (3am)⁹


Yellow solid, mp: 120-121 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.17 (m, 4H), 6.69-6.55 (m, 4H), 4.48 (dd, *J* = 8.2, 3.0 Hz, 1H), 3.88 (t, *J* = 18.3 Hz, 2H), 3.46 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.34 (dd, *J* = 11.0, 8.2 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 137.63, 129.32, 126.89, 118.88, 118.72, 114.68, 114.39, 54.44, 49.20, 21.15; HRMS (ESI) calcd for C₁₅H₁₇N₂ [M+H]⁺: 225.1386, found 225.1384.

2-(4-Methoxyphenyl)-1,2,3,4-tetrahydroquinoxaline (3an)⁹


Yellow solid, mp: 63-65 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.34-7.28 (m, 2H), 6.94-6.91 (m, 2H), 6.67-6.57 (m, 4H), 4.45 (ddd, *J* = 11.3, 8.2, 3.0 Hz, 1H), 3.84 (s, 3H), 3.45-3.42 (m, 1H), 3.34-3.29 (m, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 159.29, 134.22, 133.92, 132.85, 128.12, 118.84, 118.75, 114.65, 114.41, 114.01, 55.34, 54.09, 49.29; HRMS (ESI) calcd for C₁₅H₁₇ON₂ [M+H]⁺: 241.1335, found 242.1339.

2-([1,1'-Biphenyl]-4-yl)-1,2,3,4-tetrahydroquinoxaline (3ao)¹⁰


White solid, mp: 118-120 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (ddd, *J* = 5.8, 5.1, 4.3 Hz, 4H), 7.46-7.43 (m, 4H), 6.67-6.58 (m, 5H), 4.54 (dd, *J* = 8.0, 3.0 Hz, 1H), 3.51 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.37 (dd, *J* = 11.0, 8.1 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 140.92, 132.83, 128.82, 127.40, 127.12, 118.98, 118.84, 114.76, 114.47, 54.45, 49.09; HRMS (ESI) calcd for C₂₀H₁₉N₂ [M+H]⁺: 287.1543 found: 287.1547.

2-(4-Fluorophenyl)-1,2,3,4-tetrahydroquinoxaline (3ap)⁹


Yellow solid, mp: 103-104 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.37-7.02 (m, 4H), 6.65-6.57 (m, 4H), 4.47 (dd, *J* = 8.1, 3.0 Hz, 1H), 3.42 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.28 (dd, *J* = 11.0, 8.1 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 150.80, 142.98, 130.47, 129.65, 129.17, 128.62, 128.54, 118.95, 116.39, 115.59, 114.71, 54.02, 49.18; HRMS (ESI) calcd. for C₁₄H₁₄FN₂ [M+H]⁺: 229.1136, found: 229.1131.

2-(4-Chlorophenyl)-1,2,3,4-tetrahydroquinoxaline (3aq)⁹


Yellow solid, mp 104-105°C; ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.29 (m, 4H), 6.65-6.55 (m, 4H), 4.45 (dd, *J* = 8.0, 3.1 Hz, 1H), 3.42 (dd, *J* = 11.1, 3.1 Hz, 1H), 3.26 (dd, *J* = 11.1, 8.0 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 140.45, 133.79, 132.75, 128.81, 128.36, 119.03, 118.99, 114.77, 114.53, 54.09, 49.00; HRMS (ESI) calcd. for C₁₄H₁₄ClN₂ [M+H]⁺: 245.0840, found: 245.0833.

2-(4-Bromophenyl)-1,2,3,4-tetrahydroquinoxaline (3ar)⁹


Yellow solid, mp: 144-146°C; ¹H NMR (400 MHz, CDCl₃) δ 7.53-7.50 (m, 2H), 7.29-7.27 (m, 2H), 6.68-6.58 (m, 4H), 4.48 (dd, *J* = 8.0, 3.0 Hz, 1H), 3.46 (dt, *J* = 4.8, 2.4 Hz, 1H), 3.31 (ddd, *J* = 11.1, 8.0, 5.6 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 140.99, 133.77, 132.75, 131.76, 128.73, 121.68, 119.04, 119.00, 114.78, 114.55, 54.15, 48.93; HRMS (ESI) calcd for C₁₄H₁₄BrN₂ [M+H]⁺: 289.0335, found: 285.0329.

2-(4-(Trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline (3as)¹¹


White solid, mp: 143-144 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.68-7.49 (m, 4H), 6.77-6.50 (m, 4H), 4.58 (dd, *J* = 7.7, 3.0 Hz, 1H), 3.96 (d, *J* = 8.7 Hz, 2H), 3.50 (dd, *J* = 11.1, 3.1 Hz, 1H), 3.33 (dd, *J* = 11.1, 7.7 Hz, 1H); ¹³C NMR (CDCl₃, 100.6 MHz): δ 146.08, 133.60, 132.74, 127.88, 127.35, 126.09, 125.60, 119.15, 119.10, 114.67, 114.60, 54.36, 48.77; HRMS (ESI) calcd for C₁₅H₁₄F₃N₂ [M+H]⁺: 279.1104, found: 279.1108.

2-(*o*-Tolyl)-1,2,3,4-tetrahydroquinoxaline (3at)⁹


Yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.55-7.45 (m, 1H), 7.33-7.16 (m, 3H), 6.76-6.52 (m, 4H), 4.75 (dd, *J* = 8.2, 2.9 Hz, 1H), 3.84 (d, *J* = 7.3 Hz, 1H), 3.48 (dd, *J* = 11.1, 3.0 Hz, 1H), 3.29 (dt, *J* = 21.6, 10.8 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 139.55, 135.28, 134.47, 132.84, 130.47, 127.50, 126.66, 126.54, 118.91, 118.79, 114.72, 114.54, 77.42, 77.10, 76.78, 50.57, 47.81, 19.27; HRMS (ESI) calcd for C₁₅H₁₇N₂ [M+H]⁺: 225.1386, found 225.1381.

2-(*m*-Tolyl)-1,2,3,4-tetrahydroquinoxaline (3au)⁹


Yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.26-7.10 (m, 4H), 6.63-6.54 (m, 4H), 4.42 (dd, *J* = 8.3, 3.0 Hz, 1H), 3.90-3.79 (m, 2H), 3.42 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.30 (dd, *J* = 11.0, 8.3 Hz, 1H), 2.27-2.35(s, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 141.75, 138.36, 134.20, 132.86, 128.67, 128.57, 127.69, 124.10, 118.90, 118.78, 114.72, 114.45, 54.72, 49.23, 21.49; HRMS (ESI) calcd. for C₁₅H₁₇N₂ [M+H]⁺: 225.1386, found 225.1396.

2-(Naphthalen-1-yl)-1,2,3,4-tetrahydroquinoxaline (3av)¹¹

White solid, mp: 108-110 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.01-7.96 (m, 1H), 7.89-7.78 (m, 1H), 7.54-7.53 (m, 1H), 7.51-7.44 (m, 4H), 6.67-6.58 (m, 4H), 5.30 (dd, *J* = 7.9, 2.9 Hz, 1H), 4.05-3.75 (m, 2H), 3.65 (dd, *J* = 11.2, 3.0 Hz, 1H), 3.44-3.39 (m, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 137.17, 134.37, 134.06, 132.97, 130.49, 130.20, 129.71, 129.14, 128.21, 126.36, 125.74, 125.67, 124.12, 122.62, 119.06, 118.89, 114.89, 114.67, 50.71, 48.14; HRMS (ESI) calcd. for C₁₈H₁₇N₂ [M+H]⁺: 261.1386, found 261.1379.


(*E*)-2-Styryl-1,2,3,4-tetrahydroquinoxaline (3aw)¹⁰

Red solid, mp: 104-105 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.23 (m, 6H), 6.67-6.49 (m, 6H), 4.50 (dt, *J* = 11.5, 5.8 Hz, 1H), 3.48 (dd, *J* = 11.0, 3.1 Hz, 1H), 3.35 (dd, *J* = 11.0, 8.2 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 134.14, 132.83, 128.65, 128.55, 128.36, 127.91, 127.01, 118.89, 118.77, 114.70, 114.43, 114.32, 53.47, 49.15; HRMS (ESI) calcd. for C₁₆H₁₇N₂ [M+H]⁺: 237.1386, found: 233.1379.

2-Methyl-2,3,4,5-tetrahydro-1H-benzo[b] [1, 4] diazepine (3ax)¹²


Yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 6.76-6.69 (m, 2H), 6.44-6.37 (m, 2H), 3.51-3.45 (m, 1H), 3.31-3.27 (m, 1H), 3.04-2.99 (m, 1H), 1.83-1.79 (m, 1H), 1.64-1.57 (m, 1H), 1.17 (d, *J* = 3.5 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 121.64, 120.69, 120.13, 114.97, 52.67, 45.91, 39.48, 19.74; HRMS (ESI) calcd. for C₁₀H₁₅N₂ [M+H]⁺: 163.1230, found: 163.1234.

2-Methyl-1,2,3,4,5,6-hexahydrobenzo[b] [1, 4]diazocine (3ay)




White solid, mp: 112-114 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.71 (dd, $J = 5.7, 3.3$ Hz, 2H), 7.53 (dd, $J = 5.7, 3.3$ Hz, 2H), 4.22 (qd, $J = 10.9, 6.0$ Hz, 3H), 1.72-1.65 (m, 2H), 1.46-1.39 (m, 2H), 1.31 (d, $J = 3.0$ Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 119.64, 118.13, 117.68, 111.96, 53.67, 46.91, 31.48, 29.48, 22.75; HRMS (ESI) calcd. for $\text{C}_{11}\text{H}_{17}\text{N}_2$ $[\text{M}+\text{H}]^+$: 177.1386, found: 177.1397.

2,6-Dimethyl-1,2,3,4-tetrahydroquinoxaline (3ba₁)




Yellow solid, mp: 77-79 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.39 (ddd, $J = 27.3, 13.5, 4.7$ Hz, 3H), 3.50 (ddd, $J = 12.0, 6.0, 2.8$ Hz, 1H), 3.29 (dt, $J = 10.7, 3.3$ Hz, 1H), 3.07-2.93 (m, 1H), 2.17 (s, 3H), 1.17 (d, $J = 6.3$ Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 131.06, 130.64, 119.05, 115.20, 114.73, 48.42, 45.94, 45.87, 20.68, 19.94; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$: 163.1230, found: 163.1233.

2,7-Dimethyl-1,2,3,4-tetrahydroquinoxaline (3ba₂)




Yellow solid, mp: 75-76 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.44 (m, 3H), 3.91 (s, 3H), 3.50 (m, 1H), 3.29 (dt, $J = 10.3, 3.6$ Hz, 1H), 3.04-2.97 (m, 1H), 2.17 (s, 3H), 1.18 (d, $J = 6.7$ Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 130.61, 127.92, 118.65, 114.82, 114.35, 48.08, 45.51, 20.32, 19.58; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$: 163.1230, found: 163.1238.

6-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ca₁)⁶



White solid, mp: 90-91 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.39 (ddd, $J = 27.3, 13.5, 4.7$ Hz, 3H), 3.91 (s, 3H), 3.56-3.42 (m, 2H), 3.29 (dt, $J = 10.7, 3.3$ Hz, 1H), 3.05-2.96 (m, 1H), 1.17 (d, $J = 6.3$ Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 153.17, 134.64, 127.88, 114.76, 102.90, 100.74, 55.62, 48.01, 45.53, 19.64; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 179.1179, found: 179.1185.


7-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ca₂)



White solid, mp: 94-96 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.39 (ddd, $J = 27.3, 13.5, 4.7$ Hz, 3H), 3.91 (s, 3H), 3.56-3.42 (m, 2H), 3.29 (dt, $J = 10.7, 3.3$ Hz, 1H), 3.05-2.96 (m, 1H), 1.17 (d, $J = 6.3$ Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 153.17, 134.64, 127.88, 114.76, 102.90, 100.74, 55.62, 48.01, 45.53, 19.64; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}$


$[M+H]^+$: 179.1179, found: 179.1175.

2-Methyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoxaline (3da₁)¹³




Brown solid, mp: 112-113 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.84 (d, *J* = 8.1 Hz, 1H), 6.71 (s, 1H), 6.49 (dd, *J* = 8.1, 2.7 Hz, 1H), 3.83 (s, 1H), 3.62-3.45 (m, 1H), 3.36 (ddd, *J* = 10.8, 7.8, 3.0 Hz, 1H), 3.06 (ddd, *J* = 16.2, 10.8, 8.0 Hz, 1H), 1.22 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 136.38, 132.60, 123.60, 115.81, 112.94, 110.54, 47.57, 45.54, 19.70; HRMS (ESI) calcd. for C₁₀H₁₂F₃N₂ $[M+H]^+$: 217.0947, found: 217.0953.

2-Methyl-7-(trifluoromethyl)-1,2,3,4-tetrahydroquinoxaline (3da₂)




White solid, mp: 101-103 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.95 (d, *J* = 8.3 Hz, 1H), 6.95 (s, 1H), 6.59 (dd, *J* = 8.1, 2.4 Hz, 1H), 3.69-3.60 (m, 1H), 3.50 (ddd, *J* = 11.2, 7.3, 3.3 Hz, 1H), 3.15 (ddd, *J* = 16.2, 11.8, 8.1 Hz, 1H), 1.34 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 136.86, 133.08, 124.08, 120.53, 116.29, 113.42, 111.03, 48.06, 45.67, 21.53; HRMS (ESI) calcd. for C₁₀H₁₂F₃N₂ $[M+H]^+$: 217.0947, found: 217.0945.

6-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ea₁)




White solid, mp: 84-85 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.48-6.11 (m, 3H), 3.63-3.18 (m, 3H), 3.11-2.90 (m, 1H), 1.18 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 114.84, 103.94, 103.72, 101.15, 100.89, 48.11, 45.81, 45.51, 19.77; HRMS (ESI) calcd. for C₉H₁₂FN₂ $[M+H]^+$: 167.0979, found: 167.0977.

7-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ea₂)



Yellow solid, mp: 92-93 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.45-6.22 (m, 3H), 3.56-3.51 (m, 1H), 3.32-2.97 (m, 1H), 1.21 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 128.99, 115.11, 104.21, 103.99, 101.42, 101.16, 48.38, 46.08, 20.04; HRMS (ESI) calcd. for C₉H₁₂FN₂ $[M+H]^+$: 167.0985, found: 167.0979.


6-Chloro-2-methyl-1,2,3,4-tetrahydroquinoxaline (3fa₁)⁶



Yellow solid, mp: 86-87 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.52-6.38 (m, 3H), 3.52-3.45 (m, 1H), 3.33-3.30 (m, 1H), 3.04-2.96 (m, 1H), 1.17 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 131.53, 130.00, 117.92, 114.94, 113.76, 47.91, 45.55, 19.78; HRMS (ESI) calcd. for


$C_9H_{12}ClN_2 [M+H]^+ : 183.0684$, found: 183.0681.

7-Chloro-2-methyl-1,2,3,4-tetrahydroquinoxaline (3fa₂)




White solid, mp: 77-78 °C; 1H NMR (400 MHz, $CDCl_3$) δ 6.45-6.22 (m, 3H), 3.55-3.44(m, 1H), 3.35-3.29 (m, 1H), 3.07-2.99 (m, 1H), 1.21 (d, J = 6.2 Hz, 3H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 134.36, 131.65, 130.12, 118.03, 115.05, 113.87, 48.02, 45.67, 19.90; HRMS (ESI) calcd. for $C_9H_{12}ClN_2 [M+H]^+ : 183.0684$, found: 183.0687.

6-Bromo-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ga₁)




Dark brown solid, mp: 88-90 °C; 1H NMR (400 MHz, $CDCl_3$) δ 6.67-6.23 (m, 3H), 3.54-3.33 (m, 1H), 3.30 (dd, J = 10.8, 2.7 Hz, 1H), 3.08-2.88 (m, 1H), 1.17 (d, J = 6.3 Hz, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 120.76, 116.45, 116.35, 115.34, 115.26, 110.09, 47.81, 45.48, 19.73; HRMS (ESI) calcd. for $C_9H_{12}BrN_2 [M+H]^+ : 227.0178$, found: 227.0171.

7-Bromo-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ga₂)




Brown solid, mp: 77-80 °C; 1H NMR (400 MHz, $CDCl_3$) δ 6.60-6.29 (m, 3H), 3.46-3.40 (m, 2H), 3.27 (dd, J = 9.8, 2.5 Hz, 1H), 2.99-2.92 (m, 1H), 1.14 (d, J = 6.6 Hz, 1H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 134.98, 132.46, 120.76, 116.45, 115.34, 110.09, 47.83, 45.48, 19.73; HRMS (ESI) calcd. for $C_9H_{12}BrN_2 [M+H]^+ : 227.0178$, found: 227.0185.

2-Methyl-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile (3ha₁)




Grey solid, mp: 100-101 °C; 1H NMR (400 MHz, $CDCl_3$) δ 6.47-6.33 (m, 3H), 3.53-3.44 (m, 1H), 3.33-3.24 (m, 1H), 3.04-2.94 (m, 1H), 1.17 (d, J = 6.3 Hz, 3H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 131.06, 123.84, 119.08, 116.30, 115.17, 114.74, 112.99, 48.42, 45.87, 19.87; HRMS (ESI) calcd. for $C_{10}H_{12}N_3 [M+H]^+ : 174.1026$, found: 174.1037.


2-Methyl-1,2,3,4-tetrahydroquinoxaline-7-carbonitrile (3ha₂)




White solid, mp: 95-96 °C; 1H NMR (400 MHz, $CDCl_3$) δ 6.44-6.37 (m, 3H), 3.51-3.44 (m, 3H), 3.32-3.27 (m, 1H), 3.04-2.99 (m, 1H), 1.17 (d, J = 6.2 Hz, 3H); ^{13}C NMR (100.6 MHz, $CDCl_3$) δ 130.86, 123.64, 118.88, 116.20, 114.96, 114.53, 112.79, 48.22, 45.67, 20.48; HRMS (ESI) calcd. for $C_{10}H_{12}N_3 [M+H]^+ : 174.1026$, found: 174.1029.

Methyl 2-methyl-1,2,3,4-tetrahydroquinoxaline-6-carboxylate (3ia₁)


Yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.19 (m, 2H), 6.43 (d, *J* = 8.2 Hz, 1H), 3.83 (s, 3H), 3.62-3.57 (m, 2H), 3.47-3.06 (m, 1H), 1.23-1.16 (m, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 167.54, 138.32, 131.91, 121.69, 119.05, 115.18, 112.52, 51.51, 47.44, 45.86, 44.90, 19.83; HRMS (ESI) calcd. for C₁₁H₁₅N₂O₂ [M+H]⁺: 207.1128, found: 207.1131.

Methyl 2-methyl-1,2,3,4-tetrahydroquinoxaline-7-carboxylate (3ia₂)


Colourless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.19 (m, 2H), 6.43 (d, *J* = 7.8 Hz, 1H), 3.82 (s, 3H), 3.62-3.57 (m, 2H), 3.47-3.06 (m, 1H), 1.23-1.16 (m, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 167.54, 138.32, 131.91, 121.69, 119.05, 115.18, 112.52, 51.51, 47.44, 45.86, 44.90, 19.83; HRMS (ESI) calcd. for C₁₁H₁₅N₂O₂ [M+H]⁺: 207.1128, found: 207.1133.

2,6,7-Trimethyl-1,2,3,4-tetrahydroquinoxaline (3ja)⁸

White solid, mp: 105-106 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.33 (d, *J* = 4.9 Hz, 2H), 3.27 (m, 2H), 3.07-2.89 (m, 1H), 2.04 (s, 6H), 1.14 (dd, *J* = 21.9, 8.0 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 131.43, 130.97, 126.42, 116.37, 48.61, 46.07, 21.04, 19.88, 18.87; HRMS (ESI) calcd. for C₁₁H₁₇N₂ [M+H]⁺: 177.1386, found: 177.1381.


6,7-Dichloro-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ka)⁶

White solid, mp: 101-102 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.52 (t, *J* = 3.7 Hz, 2H), 3.53-3.37 (m, 1H), 3.30 (dd, *J* = 10.8, 3.0 Hz, 1H), 2.99 (dd, *J* = 10.7, 8.1 Hz, 1H), 1.18 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.15, 132.84, 120.27, 114.68, 114.57, 47.57, 45.35, 19.68; HRMS (ESI) calcd. for C₉H₁₁Cl₂N₂ [M+H]⁺: 217.0294, found: 217.0299.

6,7-Dibromo-2-methyl-1,2,3,4-tetrahydroquinoxaline (3la)


Brown solid, mp: 112-114 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.56 (d, *J* = 3.7 Hz, 2H), 3.53-3.49 (m, 1H), 3.36 (dd, *J* = 10.8, 3.0 Hz, 1H), 3.01 (dd, *J* = 10.7, 8.1 Hz, 1H), 1.23 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 133.14, 132.86, 118.28, 114.69, 114.57, 47.57, 45.33, 19.77; HRMS (ESI) calcd. for C₉H₁₁Br₂N₂ [M+H]⁺: 304.9283, found: 304.9291.

6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroquinoxaline (3ma)




White solid, mp: 131-132 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.25 (d, J = 4.9 Hz, 2H), 4.04 (d, J = 7.1 Hz, 6H), 3.38 (s, 2H), 3.20 (d, J = 8.8 Hz, 1H), 2.89 (d, J = 14.6 Hz, 1H), 1.09 (d, J = 6.3 Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 139.55, 139.09, 125.53, 100.48, 59.50, 47.72, 45.19, 17.99; HRMS (ESI) calcd. for $\text{C}_{11}\text{H}_{17}\text{O}_2\text{N}_2$ $[\text{M}+\text{H}]^+$: 209.1285, found: 209.1277.

2-Methyl-1,2,3,4-tetrahydrobenzo[g]quinoxaline (3na)




White solid, mp: 173-175 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.47 (dd, J = 5.9, 3.3 Hz, 2H), 7.14 (dd, J = 6.2, 3.3 Hz, 2H), 6.82 (s, 2H), 3.72-3.55 (m, 1H), 3.39 (d, J = 3.1 Hz, 1H), 3.16 (d, J = 8.5 Hz, 1H), 1.26 (d, J = 3.8 Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 134.80, 134.46, 129.08, 125.20, 125.12, 122.57, 122.49, 107.96, 107.73, 47.87, 45.76, 19.75; HRMS (ESI) calcd. for $\text{C}_{13}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$: 199.1230, found: 199.1226.

1,3-Dimethyl-1,2,3,4-tetrahydroquinoxaline (3oa)




Yellow oil; ^1H NMR (400 MHz, CDCl_3) δ 6.69-6.65 (m, 1H), 6.58-6.55 (m, 2H), 6.48 (dd, J = 7.5, 1.4 Hz, 1H), 3.62 (s, 1H), 3.15 (dd, J = 10.6, 2.4 Hz, 1H), 2.94 (t, J = 8.8 Hz, 1H), 2.85 (s, 3H), 1.17 (d, J = 6.3 Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 129.33, 126.91, 118.19, 114.42, 113.47, 111.56, 56.97, 45.67, 39.11, 20.08; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{15}\text{N}_2$ $[\text{M}+\text{H}]^+$: 163.1230, found: 163.1238.

1-Allyl-3-methyl-1,2,3,4-tetrahydroquinoxaline (3pa)




Pale-yellow oil; ^1H NMR (400 MHz, CDCl_3) δ 6.72-6.48 (m, 4H), 5.93-5.83 (m, 1H), 5.28-5.17 (m, 2H), 3.86 (dtd, J = 20.8, 16.7, 8.7 Hz, 2H), 3.57 (d, J = 6.2 Hz, 1H), 3.22 (dd, J = 10.7, 2.6 Hz, 1H), 3.04 (dd, J = 13.1, 6.0 Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 135.79, 134.48, 133.65, 119.15, 118.15, 117.55, 113.97, 111.53, 59.71, 55.15, 45.27, 19.91; HRMS (ESI) calcd. for $\text{C}_{12}\text{H}_{17}\text{N}_2$ $[\text{M}+\text{H}]^+$: 189.1286, found: 189.1282.

1-Benzyl-3-methyl-1,2,3,4-tetrahydroquinoxaline (3qa)




Colourless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.32-7.28 (m, 5H), 6.60-6.51 (m, 4H), 4.72 (s, 1H), 4.43 (s, 1H), 3.58-3.55 (m, 1H), 3.26-3.23 (m, 1H), 3.11-3.07 (m, 1H), 1.17 (d, J = 6.3 Hz, 2H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 138.77, 134.93, 133.70, 128.57, 126.99, 126.87, 119.15, 117.59, 113.97, 111.51, 55.28, 55.16, 45.31, 19.91; HRMS (ESI) calcd. for $\text{C}_{16}\text{H}_{19}\text{N}_2$ $[\text{M}+\text{H}]^+$: 239.1543, found: 239.1547.

5-Methyl-1,4,5,6-tetrahydropyrazine-2,3-dicarbonitrile (3ra)




White solid, mp: 101-102 °C; ^1H NMR (400 MHz, CDCl_3) δ 3.348-3.44 (m, 1H), 3.31- 3.28 (m, 1H), 3.00-2.96 (m, 1H), 1.18 (d, J = 6.3 Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 120.34, 120.27, 114.70, 114.58, 47.56, 45.35, 19.65; HRMS (ESI) calcd. for $\text{C}_7\text{H}_9\text{N}_4$ $[\text{M}+\text{H}]^+$: 149.0822, found: 149.0826.

3-Methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (3sa)¹⁴




Yellow oil; ^1H NMR (400 MHz, CDCl_3) δ 6.76-6.48 (m, 4H), 4.28 (m, 1H), 3.69-3.62 (m, 1H), 3.50-3.45 (m, 1H), 1.27 (dd, J = 17.4, 6.3 Hz, 3H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 143.75, 132.14, 121.20, 118.87, 116.20, 113.53, 45.87, 19.88; HRMS (ESI) calcd. for $\text{C}_9\text{H}_{12}\text{NO}$ $[\text{M}+\text{H}]^+$: 150.0913, found: 150.0921.

3-Methyl-3,4-dihydroquinoxalin-2(1H)-one (4aa)⁸




White solid, mp: 136-136 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.47(s, 1H), 6.94-6.70 (m, 4H), 4.06(m, 1H), 1.49 (d, J = 10.6 Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 170.25, 133.92, 123.94, 121.52, 119.66, 115.43, 114.15, 51.92, 17.827; HRMS (ESI) calcd. for $\text{C}_9\text{H}_{11}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 163.0866, found: 163.0869.

3-Ethyl-3,4-dihydroquinoxalin-2(1H)-one (4ab)⁸




Yellow solid, mp: 77-78 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.86-7.24 (m, 4H), 2.95(m, 2H), 1.89(m, 2H), 1.09 (t, J = 10.6 Hz, 1H); ^{13}C NMR (100.6 MHz, CDCl_3) δ 169.41, 133.41, 125.17, 122.15, 118.97, 116.71, 114.60, 51.71, 27.06, 10.03; HRMS (ESI) calcd. for $\text{C}_{10}\text{H}_{13}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 177.1022, found: 177.1029.

3-Isopropyl-3,4-dihydroquinoxalin-2(1H)-one (4ad)⁸




Yellow solid, mp: 121-123°C; ¹H NMR (400 MHz, CDCl₃) δ 9.76(s, 1H), 7.29-6.67 (m, 4H), 4.09(s, 1H), 3.81(s, 1H), 2.28 (d, *J* = 10.6 Hz, 1H), 1.08-1.01(dd, *J* = 17.4, 16.3 Hz, 6H); ¹³C NMR (100.6 MHz, CDCl₃) δ 168.83, 133.31, 124.89, 123.91, 118.79, 115.51, 113.39, 81.77, 30.83, 20.23, 19.04, 17.508; HRMS (ESI) calcd. for C₁₁H₁₅N₂O [M+H]⁺: 191.1179, found: 191.1181.

3-Benzyl-3,4-dihydroquinoxalin-2(1H)-one (4aj)¹⁵




Yellow solid, mp: 188-189 °C; ¹H NMR (400 MHz, CDCl₃) δ 10.04(s, 1H), 7.40-7.25 (m, 5H), 6.93-6.61(m, 4H), 4.12 (d, *J* = 10.6 Hz, 1H), 3.95 (s, 1H), 3.32(m, 1H), 2.93 (m, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 169.28, 136.91, 132.43, 129.49, 128.99, 127.09, 125.56, 124.12, 119.60, 115.82, 114.59, 57.82, 37.57; HRMS (ESI) calcd. for C₁₅H₁₅N₂O [M+H]⁺: 239.1179, found: 239.1177.

3-Phenyl-3,4-dihydroquinoxalin-2(1H)-one (4al)¹⁶




White solid, mp: 79-81 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.39-7.25 (m, 5H), 6.84 (m, 1H), 6.63-6.56(m, 3H), 5.09 (s, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 177.13, 139.13, 132.82, 129.91, 127.00, 122.90, 118.78, 115.70, 114.42, 53.46; HRMS (ESI) calcd. for C₁₄H₁₃N₂O [M+H]⁺: 225.1022, found: 225.1017.

(E)-3-styryl-3,4-dihydroquinoxalin-2(1H)-one (4aw)¹⁷




White solid, mp: 134-136°C; ¹H NMR (400 MHz, CDCl₃) δ 8.24-8.20 (m, 1H), 7.92-7.74 (m, 4H), 7.52-7.41(m, 6H), 4.42 (d, *J* = 6.3 Hz, 1H); ¹³C NMR (100.6 MHz, CDCl₃) δ 169.78, 140.77, 133.06, 131.76, 127.58, 126.83, 125.93, 117.82, 117.70, 117.27, 113.62, 113.35, 113.25, 61.14; HRMS (ESI) calcd. for C₁₆H₁₅N₂O [M+H]⁺: 251.1179, found: 251.1173.

3,6,7-Trimethyl-3,4-dihydroquinoxalin-2(1H)-one (4ja)¹⁶




Yellow solid, mp: 125-127°C; ¹H NMR (400 MHz, CDCl₃) δ 6.33-6.32 (m, 2H), 3.99 (s, 1H), 3.79 (s, 1H), 2.14 (s, 6H), 1.32 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 170.43, 133.97, 126.47, 123.42, 117.79, 116.38, 51.62, 19.89, 18.87; HRMS (ESI) calcd. for C₁₁H₁₅N₂O [M+H]⁺: 191.1179, found: 191.1183.

4-Methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one (4ax)¹⁸




Yellow solid, mp: 110-113°C; ¹H NMR (400 MHz, CDCl₃) δ 7.33-7.07 (m, 4H), 3.26 (m, 1H), 2.66 (m, 1H), 2.28 (m, 1H), 1.24 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 170.43, 138.99, 133.98, 126.47, 123.42, 117.79, 116.38, 51.62, 41.38, 23.89; HRMS (ESI) calcd. for C₁₀H₁₃N₂O [M+H]⁺: 177.1022, found: 177.1028.

5-Methyl-6-oxo-1,4,5,6-tetrahydropyrazine-2,3-dicarbonitrile (4ua)¹⁹



White solid, mp: 239-240 °C; ¹H NMR (400 MHz, CDCl₃) δ 3.55 (m, 1H), 1.60 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 151.56, 116.02, 115.70, 111.74, 100.41, 55.34, 14.35; HRMS (ESI) calcd. for C₇H₇N₄O [M+H]⁺: 163.0614, found: 163.0621.


3-Methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-one (4ya)²⁰




Colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.03-6.76 (m, 4H), 3.99 (m, 1H), 1.55 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100.6 MHz, CDCl₃) δ 166.14, 144.55, 137.11, 123.60, 120.44, 116.38, 114.38, 50.85, 21.31; HRMS (ESI) Calcd for C₉H₁₀NO₂ [M+H]⁺: 164.0706, found: 164.0710.


5. The mechanistic study

1) ESI-MS Study






2) General procedure for the reaction of 1a with 2a



A mixture of *o*-phenylenediamine **1a** (27.5 mg, 0.25 mmol), ethyl 2-oxopropanoate **2a** (31.93 mg, 0.275 mmol) and toluene (1.5 mL) with or without $\text{B}(\text{C}_6\text{F}_5)_3$ (6.4 mg, 5.0 mol%) in an oven-dried screw-capped pressure tube was stirred at 110 °C for 1 h. After cooling to ambient temperature, the volatiles were removed under reduced pressure, and the reaction mixture was purified by column chromatography on silica gel using a mixture of ethyl acetate and hexane to give the target compound **5aa** as a light solid.


3) General procedure for the synthesis 3aa from 5aa



A mixture of 3-methylquinoxalin-2(1*H*)-one **5aa** (40.04 mg, 0.25 mmol), $\text{B}(\text{C}_6\text{F}_5)_3$ (6.4 mg, 5.0 mol%) and PMHS (0.06 mL, 1.0 mmol) in toluene (1.5 mL) in an oven-dried screw-capped pressure tube was stirred at 110 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0 mL) was added to the reaction mixture, which was extracted with EtOAc three times (5.0 mL each). The combined organic phases were dried over Na_2SO_4 , filtered and evaporated

under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by column chromatography on silica gel using a mixture of ethyl acetate and hexane to give the target compound **3aa** as a light yellow oil.

4) General procedure for the synthesis **3aa** from **4aa**





A mixture of **4aa** (40.55 mg, 0.25 mmol), B(C₆F₅)₃ (6.4 mg, 5.0 mol%) and PMHS (0.06 mL, 1.0 mmol) in toluene (1.5 mL) in an oven-dried screw-capped pressure tube was stirred at 110 °C for 16 h. After cooling to ambient temperature, the mixture was diluted with EtOAc (5.0 mL). Then water (5.0 mL) was added to the reaction mixture, which was extracted with EtOAc three times (5.0 mL each). The combined organic phases were dried over Na₂SO₄, filtered and evaporated under reduced pressure. After the removal of volatile materials by rotary evaporation, the resultant mixture was purified by column chromatography on silica gel using a mixture of ethyl acetate and hexane to give the target compound **3aa** as a light yellow oil.



6. References:



1. J. Shao, J. Chang, C. Chi, *Org. Biomol. Chem.* **2012**, *10*, 7045–7052.
2. L. Perrin, P. Hudhomme, *Eur. J. Org. Chem.* **2011**, 5427-5440.
3. X. Creary, *J. Org. Chem.* **1987**, *52*, 5026-5030.
4. a) X. Ren, H. Du, *J. Am. Chem. Soc.* **2016**, *138*, 810-813; b) Z. Zhang, H. Du, *Angew. Chem. Int. Ed.* **2015**, *54*, 623-626.
5. Y. Gang, J-K. Wei, T. Liu, L. Wu, W-H. Zhang, *Adv. Synth. Catal.*, **2017**, *359*, 933-940.
6. N. Arai, Y. Saruwatari, K. Isobe, T. Ohkuma, *Adv. Synth. Catal.*, **2013**, *355*, 2769-2774.
7. D. Cartigny, T. Nagano, T. Ayad, J.-P. Genêt, T. Ohshima, K. Mashima, V. Ratovelomanana-Vidal, *Adv. Synth. Catal.*, **2010**, *352*, 1886-1891.



8. L. Zhang, R. Qiu, X. Xue, Y. Pan, C. Xu, H. Li, L. Xu, *Adv. Synth. Catal.*, **2015**, 357, 3529-3537.
9. T. Nagano, A. Iimuro, R. Schwenk, T. Ohshima, Y. Kita, A. Togni, K. Mashima, *Chem. Eur. J.*, **2012**, 18, 11578-11592.
10. J. Tan, W. Tang, Y. Sun, Z. Jiang, F. Chen, L. Xu, Q. Fan, J. Xiao, *Tetrahedron*, **2011**, 67, 6206-6213.
11. Q.-A. Chen, K. Gao, Y. Duan, Z.-S. Ye, L. Shi, Y. Yang, Y.-G. Zhou, *J. Am. Chem. Soc.* **2012**, 134, 2442-2448.
12. N. Kalyanam, S. Manjunatha, *Heterocycles*, **1991**, 32, 1131-6.
13. V. Krchnak, J. Smith, J. Vagner, *Tetrahedron. Lett.*, **2001**, 42, 2443-2446.
14. K. Marichev, J. Takacs, *ACS. Catal.*, **2016**, 6, 2205-2210.
15. S. David V, M. Sukhdev, C. Yves A, L. Silvana, W. Amal, Y. Theresa, P. F. Marielle, M. Christiane, Z. Li, L. Anne-Marie, N. Alina, R. Jubrail, L. Sylvain, P. Anthony, B. Jeffrey, M. D. Robert, *Bio. Med. Chem. Lett.*, **2009**, 19, 4119-4121.
16. S. Kamila, E. Biehl, *Heterocycles*, **2006**, 68, 1931-1939.
17. N. Petasis, Z. Patel, *Tetrahedron. Letters*, **2000**, 41, 9607-9611.
18. C. Subhash, C-R. Tang, A. Mohammed, J. Joazaizulfazli, P. Ashok, B. Hadda, S. Mohd, Y.-T. Zheng, S. Murugesan, *Bioorganic. Chemistry*, **2017**, 72, 74-79.
19. Y. Ohtsuka, *J. Org. Chem.* **1976**, 41, 629-33.
20. L.-Q. Lu, Y. Li, K. Junge, M. Beller, *Angew. Chem. Int. Ed.*, **2013**, 52, 8382-8386.



7. ^1H and ^{13}C NMR spectra of the products














































































































































































































































8.HPLC CHART




(S)-2-methyl-1,2,3,4-tetrahydroquinoxaline
Chiralcel OD-H
Hexane / i-PrOH = 95/5 0.5ml/min, 230 nm
tr = 12.207 (S) and 15.687 (R)
ee = 47.76 $[\alpha]_D^{25} = -15.8$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	11.138			45.02	3494384	153778	21.340	
2	13.427			54.98	4267952	167054	23.993	RM



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	12.207			26.12	434839	11936	33.039	RM
2	15.687			73.88	1235623	41091	34.213	




(S)-2-ethyl-1,2,3,4-tetrahydroquinoxaline

Chiralcel OD-H


Hexane / i-PrOH = 95/5 1ml/min, 230 nm

$t_r = 6.483$ (S) and 7.890 (R)


ee = 52.56 $[\alpha]_D^{25} = -13.1$ (c 1.00, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	6.330			50.14	1544736	54151	26.789	
2	7.847			49.86	1535866	38997	36.987	R



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	6.483			23.72	315556	10150	26.578	
2	7.890			76.28	1015008	30865	39.098	R




(S)-2-isopropyl-1,2,3,4-tetrahydroquinoxaline

Chiralcel OD-H


Hexane / i-PrOH = 95/5 0.5ml/min, 230 nm

$t_r = 15.009$ (S) and 18.503 (R)


ee = 51.74 $[\alpha]_D^{25} = -13.8$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	12.283			49.43	4050312	68690	55.375	
2	14.042			50.57	4143650	83052	46.854	R



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	15.099			24.13	375764	5823	57.059	
2	18.503			75.87	1180705	21691	54.149	




(S)-2-benzyl-1,2,3,4-tetrahydroquinoxaline

Chiralcel OD-H


Hexane / i-PrOH = 95/5 0.5 ml/min, 230 nm

$t_r = 16.512$ (S) and 21.259 (R)


$ee = 58.72$ $[\alpha]_D^{25} = -14.7$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	15.733			49.88	5020836	145073	32.502	R
2	20.255			50.12	5064528	131702	37.459	



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	16.512			20.64	527768	13377	37.051	LR
2	21.259			79.36	2076275	57996	37.813	




(S)-2-phenyl-1,2,3,4-tetrahydroquinoxaline

Chiralcel OD-H


Hexane / i-PrOH = 99/1 1 ml/min, 230 nm

$t_r = 4.660$ (S) and 6.127 (R)


ee = 76.28 $[\alpha]_D^{25} = +75.8$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	4.713			48.79	1036583	52401	18.577	R
2	6.788			51.21	1087889	61699	16.559	



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	4.660			88.14	23794880	1258552	17.755	
2	6.127			11.86	3201136	135575	16.009	R




(S)-3-methyl-3,4-dihydroquinoxalin-2(1H)-one
Chiralcel OD-H


Hexane / i-PrOH = 99/1 1 ml/min, 230 nm

$t_r = 30.480$ (S) and 37.352 (R)


ee = 57.38 $[\alpha]_D^{25} = -18.7$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	29.243			50.26	10814813	191644	52.996	LRM
2	36.350			49.74	10701593	172107	58.394	RM



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	30.408			21.31	1804163	38161	44.399	
2	37.352			78.69	6617117	140402	57.638	RM




(S)-3-ethyl-3,4-dihydroquinoxalin-2(1H)-one

Chiralcel OD-H


Hexane / i-PrOH = 97/3 1 ml/min, 230 nm

$t_r = 20.048$ (S) and 24.951 (R)


$ee = 61.88$ $[\alpha]_D^{25} = -13.2$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	19.197			49.95	14083683	262609	50.364	
2	23.010			50.05	14113923	230927	57.397	



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	20.048			19.06	789367	16012	45.124	RM
2	24.951			80.94	3319737	71007	53.163	RM




(S)-3-isopropyl-3,4-dihydroquinoxalin-2(1H)-one

Chiralcel OD-H


Hexane / i-PrOH = 99/1 0.5 ml/min, 230 nm

$t_r = 57.695$ (S) and 65.833 (R)


ee = 60.96 $[\alpha]_D^{25} = -18.4$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	58.387			49.71	7982398	112013	66.924	LM
2	66.809			50.29	8074100	99588	76.138	LRM



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	57.695			19.52	2458331	19511	66.896	LRM
2	65.833			80.48	5869866	73805	74.689	




(S)-3-benzyl-3,4-dihydroquinoxalin-2(1H)-one

Chiralcel OD-H


Hexane / i-PrOH = 98/2 1 ml/min, 230 nm

$t_r = 17.717(S)$ and $26.785(R)$


$ee = 71.00$ $[\alpha]_D^{25} = -20.7$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	17.302			49.67	1053552	33902	29.184	L
2	25.815			50.33	1536864	29484	48.951	RM



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	17.717			14.5	510535	14054	44.802	RM
2	26.785			85.5	3011201	86558	32.670	RM




(S)-3-phenyl-3,4-dihydroquinoxalin-2(1H)-one

Chiralcel OD-H


Hexane / i-PrOH = 99/1 1 ml/min, 230 nm

$t_r = 29.800$ (R) and 34.011 (S)

ee = 82.24 $[\alpha]_D^{25} = +73.8$ (c 1.06, EtOH)



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	28.980			49.36	33671818	448267	70.542	
2	33.053			50.64	34545638	392887	82.574	



	保留时间	组份名称	校正因子	浓度	峰面积	峰高	半高峰宽	峰标志
1	29.800			8.881	126896	21624	57.918	R
2	34.011			91.12	13970650	189487	69.239	RM